pdf   xlsx method abbreviations

mNSCLC - L1 - PDL1 negative, nivolumab based treatment versus platinum derivate, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.78 [0.60, 1.02]< 10%1 study (1/-)96.7 %NAnot evaluable crucial-
progression or deaths (PFS) 0.73 [0.56, 0.95]< 10%1 study (1/-)99.0 %NAnot evaluable important-

safety endpoints 00

STRAE (any grade) 1.75 [1.00, 3.09]< 10%1 study (1/-)2.6 %NAnot evaluable non important-
STRAE (grade 3-4) 2.05 [1.12, 3.76]< 10%1 study (1/-)1.0 %NAnot evaluable non important-
TRAE (any grade) 3.42 [1.76, 6.65]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE (grade 3-4) 2.35 [1.53, 3.60]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 4.33 [0.48, 39.16]< 10%1 study (1/-)9.7 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 0.89 [0.48, 1.63]< 10%1 study (1/-)65.2 %NAnot evaluable non important-
TRAE leading to discontinuation (grade 3-4) 0.80 [0.38, 1.70]< 10%1 study (1/-)72.1 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Anaemia TRAE (grade 3-4) 1.34 [0.75, 2.38]< 10%1 study (1/-)16.3 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 1.06 [0.07, 17.15]< 10%1 study (1/-)48.3 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 0.26 [0.01, 5.89]< 10%1 study (1/-)79.7 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 1.43 [0.32, 6.48]< 10%1 study (1/-)32.2 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 1.06 [0.15, 7.64]< 10%1 study (1/-)47.5 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 2.18 [0.65, 7.39]< 10%1 study (1/-)10.5 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.85 [0.22, 3.21]< 10%1 study (1/-)59.6 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 1.19 [0.63, 2.24]< 10%1 study (1/-)29.4 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 1.06 [0.02, 53.93]< 10%1 study (1/-)48.8 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 2.13 [0.07, 64.04]< 10%1 study (1/-)33.3 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 1.43 [0.32, 6.48]< 10%1 study (1/-)32.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons